Resultater fra et forsøg (ACTG 241) evaluerede triple behandling med VIRAMUNE, zidovudin og didanosin sammenlignet med zidovudin + didanosin, hos 398 HIV- 1 smittede patienter (gennemsnitlig 153 CD4+ celler mm3; plasma HIV- 1 RNA 4, 59 log10 kopier/ ml) som havde modtaget mindst 6
Results from a trial (ACTG 241) evaluated triple therapy with VIRAMUNE, zidovudine and didanosine compared to zidovudine + didanosine, in 398 HIV-1 infected patients (mean baseline 153 CD4+ cells/ mm3; plasma HIV-1 RNA 4.59 log10 copies/ ml), who had received at least 6 months of NRTI therapy prior to enrolment (median 115 weeks).